Incidence of Kidney Disease

RECENT NEWS
TechCrunch  8 hrs ago  Comment 
 Sufferers of chronic kidney disease (CKD) in the United States are among the more active practitioners of disease self-management. It involves, among other disciplines, rigorous self-monitoring of blood glucose and blood pressure levels, strict...
FierceBiotech  Sep 8  Comment 
When the FDA came through with their expected approval for Keryx's ferric citrate (formerly Zerenex), a new treatment to deal with complications of kidney disease, on Friday, a label warning that the drug could wind up triggering iron overload...
DailyFinance  Sep 3  Comment 
LAVAL, QUEBEC -- (Marketwired) -- 09/03/14 -- ProMetic Life Sciences Inc. (TSX: PLI)(OTCQX: PFSCF), ("ProMetic" or the "Corporation") announced today it had a successful Pre-Investigational New Drug ("Pre-IND) meeting with the US Food and Drug...
MedPage Today  Aug 27  Comment 
(MedPage Today) -- A hypertension self-management program reduced systolic blood pressure in high-risk patients, including those with cardiovascular disease, diabetes, or chronic kidney disease, according to British researchers.
MedPage Today  Aug 22  Comment 
(MedPage Today) -- In patients with chronic kidney disease, coronary artery calcium (CAC) levels were linked more strongly with cardiovascular risk than other standard predictors.
newratings.com  Jul 30  Comment 
BASEL (dpa-AFX) - Silence Therapeutics plc.(SLN.L) said that licence holder Quark Pharmaceuticals Inc. has confirmed favourable results in its Phase 2 trial for the use of QPI-1002 short interfering RNA or siRNA for the prevention of delayed graft...
MedPage Today  Jul 18  Comment 
(MedPage Today) -- An investigational drug for secondary hyperparathyroidism in chronic kidney disease patients on dialysis met its primary endpoint, Amgen announced.
Wall Street Journal  Jul 17  Comment 
Amgen Inc. said its experimental treatment for secondary hyperparathyroidism in chronic kidney disease showed positive results in a phase III study.
Benzinga  Jul 17  Comment 
Amgen (NASDAQ: AMGN) today announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its...
MedPage Today  Jul 8  Comment 
(MedPage Today) -- What pearls can be gleaned from an epidemic of chronic kidney disease in Central America? That's the focus of tonight's Nephrology Journal Club, held online at 9 p.m. ET.




 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki